IGC · IGC Pharma Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 0.19 USD |
|---|---|
| 1-day change | -2.1% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 10 / 25 / 20 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 2 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +83.2% |
| Distance from 52-week high | +53.5% |
| Market cap (USD) | $33.6M |